Last reviewed · How we verify
NCT04796688
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Phase 1 trial testing Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells in Acute Lymphoblastic Leukemia in 27 participants. Status unknown.
10 March 2023
Quick facts
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 10 March 2021 |
| Primary completion | 10 March 2023 |
| Estimated completion | 10 March 2024 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells — full drug profile →
Conditions studied
- Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
- Chronic Lymphoblastic Leukemia — all drugs for Chronic Lymphoblastic Leukemia →
- B-cell Lymphoma — all drugs for B-cell Lymphoma →
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Who can join
Adults 14 to 78, any sex, with Acute Lymphoblastic Leukemia or Chronic Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Natural killer cells in antitumour adoptive cell immunotherapy.
Laskowski TJ, Biederstädt A, Rezvani K. · · 2022 · cited 547× · PMID 35879429 · DOI 10.1038/s41568-022-00491-0 -
CAR-T: What Is Next?
Chen YJ, Abila B, Mostafa Kamel Y. · · 2023 · cited 160× · PMID 36765623 · DOI 10.3390/cancers15030663 -
CAR-NK cells for cancer immunotherapy: from bench to bedside.
Zhang L, Meng Y, Feng X, Han Z. · · 2022 · cited 144× · PMID 35303962 · DOI 10.1186/s40364-022-00364-6 -
Natural killer cells: a promising immunotherapy for cancer.
Chu J, Gao F, Yan M, Zhao S, et al · · 2022 · cited 140× · PMID 35606854 · DOI 10.1186/s12967-022-03437-0 -
Development of NK cell-based cancer immunotherapies through receptor engineering.
Page A, Chuvin N, Valladeau-Guilemond J, Depil S. · · 2024 · cited 123× · PMID 38443448 · DOI 10.1038/s41423-024-01145-x -
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w -
NK cell-based tumor immunotherapy.
Zhang H, Yang L, Wang T, Li Z. · · 2024 · cited 68× · PMID 37601277 · DOI 10.1016/j.bioactmat.2023.08.001 -
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
Zhang B, Yang M, Zhang W, Liu N, et al · · 2024 · cited 50× · PMID 38221520 · DOI 10.1038/s41419-024-06438-7
Verify or expand the search:
- PubMed search for NCT04796688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
Trials testing the same drug.
- NCT04796675 — Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies · Phase 1 · unknown
Other recruiting trials for Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
- NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
- NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting
Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
- NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
- NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
- NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
- NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04796688 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Last refreshed: 15 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04796688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing